Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-01-26

FDA Approved: SOLOSEC — Supplemental Application (Evofem Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SoLOSEC (secnidazole) from Evofem Inc., expanding the product's labeling/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SOLOSEC (secnidazole)

Snippet

SUPPL AP for SOLOSEC (SECNIDAZOLE)